Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Date:1/29/2009

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EST.

Interested participants and investors may access the conference call at 5 p.m. EST by dialing 877-675-4756 (U.S./Canada) or 719-325-4870 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8627644.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
2. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
6. Amicus Therapeutics Opens Research Facility in San Diego
7. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Amicus Therapeutics Announces First Quarter 2008 Financial Results
10. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
Breaking Biology News(10 mins):